More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one backdated for November 24 for Daiichi Sankyo’s tenosynovial giant cell ...

Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...

Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...

Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...

Daiichi Sankyo’s Dr Michael Zaiac discusses how AI, biomarkers and targeted therapies are shaping oncology’s future.

The U.S. Federal Circuit Court of Appeals has vacated a previous infringement judgment and damages award against Daiichi Sankyo in a patent dispute with Seagen Inc. This decision nullifies the earlier ...

In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...

The latest untitled letter from the FDA’s Office of Prescription Drug Promotion zeroes in on a patient testimonial video about Daiichi Sankyo’s tenosynovial giant cell tumor (TGCT) treatment, Turalio.

On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S.

The US Court of Appeals for the Federal Circuit reversed a district court’s denial of a motion for judgment as a matter of law (JMOL), finding ...

The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems ...

TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization ...